Chonluten
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
What it is
A synthetic tripeptide marketed as a bioregulator for bronchial mucosal support and anti-inflammatory, antioxidant action. The case is almost entirely preclinical and mechanism-only, randomized human trials remain unverified, and nearly all research traces to one lab with no independent replication. Long-term human safety is unknown. Not an approved drug in the US, and unregulated products sold online are of uncertain purity.
Read Full recordStudied uses & evidence
Studied uses(5)
Anti-inflammatory modulation
LowReduced TNF-alpha and IL-6 release in one human immune cell study, not independently replicated.
Bronchial mucosal support
SpeculativeBased on a developer comparison with standard-treatment controls; randomization was not reported and benefit remains unconfirmed.
Antioxidant gene regulation
SpeculativeMentioned only in review articles; no primary study has measured this effect directly.
Evidence limits
- Evidence Level
- Preclinical
Evidence consists primarily of one well-designed in vitro study (Avolio et al. 2022, IJMS) using THP-1 monocytic cells, plus preclinical animal studies and mechanistic investigations from Khavinson's group. Most claims about bronchial mucosal support derive from the broader Khavinson bioregulatory peptide framework rather than Chonluten-specific clinical trials. The related tetrapeptide Bronchogen (AEDL) has more published data on bronchial gene expression. Evidence is limited and predominantly from a single research group.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(8)
Risks = level of concern: High · Moderate · Low · Theoretical
Human evidence is limited to weak developer reports; randomized clinical benefit remains unconfirmed.
HighAlmost all research originates from a single group (Khavinson / St. Petersburg Institute of Bioregulation and Gerontology) — no independent replication
HighLong-term safety profile in humans is unknown
ModeratePotential allergic reactions or individual intolerance
LowContraindicated during pregnancy and lactation (per manufacturer)
LowQuality varies among unregulated products sold online — no pharmaceutical-grade standardization
ModerateIncreased apoptosis observed in vitro (Avolio et al. 2022) — implications for healthy tissue unclear
LowGene expression modulation effects on pre-existing conditions (e.g., cancer) are unstudied
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.